Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Antiviral Activity of PGT121 in HIV
NCT02960581Phase 1Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Nov 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PGT121 in human immunodeficiency virus infection (HIV) (9 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Proportion of participants with PGT121 mAb reactogenicity, related AEs and SAEs at 6 months, Pharmacokinetics: elimination half-life (t1/2) at 6 months and 4 more. Started Nov 2016; status: completed.
02
Drugs
PGT121
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02960581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960581.